ClinicalTrials.gg
Not yet recruitingNCT07848490Updated Sep 30, 2026

Osteoporosis & Renal Disease: Research in Primary Health Care Services

An observational study in Osteoporosis and Chronic Kidney Disease Mineral and Bone Disorder, sponsored by Universidade do Porto. Not yet recruiting at 1 site in Portugal. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Universidade do Porto · Observational

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
622
Ages
40 Years to 90 Years
Sex
All
01

Study summary

Osteoporosis, a silent and multifactorial systemic skeletal disorder, severely compromises bone strength and significantly increases the risk of fragility fractures. Despite its high prevalence (affecting \~10% of Portuguese over 50), it remains critically underdiagnosed and undertreated, with over 80% of fragility fractures occurring in untreated individuals.

Chronic Kidney Disease (CKD) profoundly exacerbates bone fragility, giving rise to CKD-associated osteoporosis, a complex skeletal disorder often integrated within CKD-Mineral and Bone Disorder. This systemic dysregulation of mineral metabolism not only impairs bone quality but also actively promotes vascular calcification and significantly elevates cardiovascular disease risk, underscoring a critical kidney-bone-vascular nexus. Despite these well-established links, CKD-associated osteoporosis is similarly underdiagnosed and undertreated, partly due to diagnostic challenges related to Bone Mineral Density interpretation and therapeutic hesitancy in this complex patient population.

This multi-phase observational study is designed to address the significant public health challenges posed by osteoporosis and by osteoporosis associated with CKD in Portugal, particularly among individuals aged 40 years to 90 years. The study aims to enhance understanding of disease prevalence, identify diagnostic and treatment gaps, and evaluate management trajectories, while emphasizing the intricate interrelationships among bone health, renal function, and cardiovascular risk.

02

Conditions studied

  • Osteoporosis
  • Chronic Kidney Disease Mineral and Bone Disorder

Keywords

  • Osteoporosis
  • Chronic Kidney Disease
  • Chronic Kidney Disease Mineral and Bone Disorder
03

In context

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

This study's planned enrollment of 622 is above the median of 160 across 456 observational studies indexed under Osteoporosis.

Browse Osteoporosis studies →

Lead sponsor

Universidade do Porto is the lead sponsor of 174 studies on the registry; 53 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population comprises adults aged 40 to 90 years registered at the Primary Healthcare Units of the ULS de Barcelos/Esposende

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 40 years and 90 years;
  • Registered at participating Primary Healthcare Unit;
  • Capable of providing .

Exclusion criteria

Exclusion Criteria:

  • \<12 months;
  • Severe cognitive/physical impairment;
  • Inability to undergo DXA.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
622 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testFracture risk assessment tool (FRAX)

    A random sample stratified by age and gender distribution from the pre-screening USF list will undergo osteoporotic fracture risk assessment via a validated, Portugal-adapted FRAX® algorithm conducted via structured telephone interviews.

  • Diagnostic testDual-Energy X-ray Absorptiometry (DXA)

    All participants with a moderate/high fracture risk for osteoporosis will undergo Bone Mineral Density assessment by DXA, as well as a subsample of low fracture risk patients.

06

What researchers measure

Primary outcomes

  1. Prevalence of Osteoporosis

    Weighted proportion of the population screened (individuals aged between 40 and 90 years) diagnosed with osteoporosis by Dual-Energy X-ray Absorptiometry (T-score ≤ -2.5).

    Time frame: Baseline

Secondary outcomes

  1. Fracture Risk

    Fracture risk assessment with the Portuguese-adapted FRAX®. Patients will be categorized in low fracture risk, moderate fracture risk and high fracture risk.

    Time frame: Baseline

  2. Prevalence of CKD-associated Osteoporosis

    Proportion of individuals with CKD meeting osteoporosis diagnostic criteria

    Time frame: Baseline and 3 months

  3. Creatinine

    Serum levels of Creatinine (mg/dL)

    Time frame: Baseline, 3 months and 12 months

  4. eGFR

    Estimated glomerular filtration rate (eGFR) calculated by the CKD-EPI equation.

    Time frame: Baseline, 3 months and 12 months

  5. Calcium

    Serum levels of Calcium (mg/dL)

    Time frame: Baseline and 12 months

  6. Phosphate

    Serum levels of phosphate (mg/dL)

    Time frame: Baseline and 12 months

  7. Alkaline phosphatase

    Serum levels of Alkaline phosphatase (U/L)

    Time frame: Baseline and 12 months

  8. 25-Hydroxyvitamin D

    Serum levels of 25-Hydroxyvitamin D (ng/mL)

    Time frame: Baseline and 12 months

  9. Parathyroid Hormone

    Serum levels of Parathyroid Hormone (pg/mL)

    Time frame: Baseline and 12 months

  10. P1NP

    Serum levels of N-terminal propeptide of type 1 procollagen (P1NP) (ng/mL)

    Time frame: Baseline and 12 months

  11. CTX

    Serum levels of C-terminal cross-linked telopeptide of type 1 collagen (CTX) (pf/mL)

    Time frame: Baseline and 12 months

  12. Health-related quality of life score (EQ-5D-5L)

    Quality of life evaluated using the EQ-5D-5L questionnaire, assessing disease control trajectories and comparing individuals with osteoporosis, with and without CKD.

    Time frame: Baseline and 12 months

  13. Medication adherence score (ERAM-7)

    Adherence to pharmacological treatment evaluated using the scale "Escala de AutoReporte de Adesão à Medicação" (ERAM-7).

    Time frame: Baseline and 12 months

Other outcomes

  1. Sclerostin

    Serum levels of Sclerostin (pmol/L)

    Time frame: Baseline and 12 months

  2. RANKL

    Serum levels of RANKL (Receptor Activator of NF-KB Ligand) (pg/mL)

    Time frame: Baseline and 12 months

  3. Osteoprotegerin

    Serum levels of Osteoprotegerin (pg/mL)

    Time frame: Baseline and 12 months

  4. FGF23

    Serum levels of FGF23 (Fibroblast Growth Factor-23) (RU/mL)

    Time frame: Baseline and 12 months

07

Study locations

1 site
  • ULS de Barcelos/Esposende
    Barcelos, 4750-333, Portugal
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2027, 11 months later.

Of 115 non-industry observational studies under Osteoporosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 113. This study's planned 11 months is below that.

Counting every sponsor, half of 126 studies reached it within 51 months; a quarter within 24 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 30, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07848490
Collaborators
ULS Barcelos/Esposende
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Janete Santos, PhD
Contact
sjanete@med.up.pt
+351 220 426 569
Carlos Vaz, MD, PhD
Contact
carlosvaz@med.up.pt

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion